International Variations in Glioblastoma Management: A Comprehensive Review - Report - MDSpire

International Variations in Glioblastoma Management: A Comprehensive Review

  • By

  • Reuben Christopher

  • Livia Stauner

  • Mathias Spendel

  • Arwin Rezai

  • Alexander Romagna

  • Christoph Schwartz

  • March 27, 2026

  • 0 min

Share

Clinical Report: International Variations in Glioblastoma Management

Overview

Revise to emphasize the evaluation of economic differences in glioblastoma management.

Background

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of only 15-17 months despite advances in treatment. The Stupp protocol, which combines surgery, radiotherapy, and chemotherapy, is the standard of care but is resource-intensive and costly. Understanding the economic implications of GBM management is crucial for optimizing treatment strategies and healthcare resource allocation globally.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • GBM has a high recurrence rate, with over 50% of patients experiencing tumor recurrence within seven months of treatment initiation.
  • The Stupp protocol remains the gold standard for GBM treatment, integrating surgery, radiotherapy, and temozolomide chemotherapy.
  • Cost-effectiveness of GBM treatments varies significantly across different healthcare systems, influenced by local willingness-to-pay thresholds.
  • Modern management strategies include the use of molecular testing and tumor treating fields (TTF) to enhance patient outcomes.
  • Economic evaluations are essential to determine the viability of new therapies in the context of existing healthcare resources.

Clinical Implications

Healthcare professionals should be aware of the significant economic burden associated with GBM management and the variability in treatment costs across different regions. Incorporating cost-effectiveness analyses into clinical decision-making can help optimize resource allocation and improve patient outcomes.

Conclusion

Strengthen the conclusion by emphasizing the role of economic evaluations in treatment decisions.

References

  1. Journal of Neuro-Oncology, Advancements in Surgical Approaches for Grade 4 Glioma: A Systematic Review from the Neuro-Oncology Division of the Italian Society of Neurosurgery (SINch®), 2023
  2. Journal of Neuro-Oncology, Contemporary Approaches to the Surgical Treatment of Incidental Gliomas, 2022
  3. Comparison of Radiotherapy and Bevacizumab-Enhanced Radiotherapy for Managing Recurrent High-Grade Gliomas: A Systematic Review, 2021
  4. The ASCO Post, New ASCO-SNO Guideline Addresses Treatment Recommendations Tailored to Glioma Subtypes, 2022
  5. Radiotherapy plus Concomitant and Adjuvant... : New England Journal of Medicine, 2023
  6. Radiotherapy plus Concomitant and Adjuvant... : New England Journal of Medicine
  7. https://virtualtrials.org/pdf2025/cns.pdf
  8. Study Details | NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | ClinicalTrials.gov

Original Source(s)

Related Content